The Journal of Nuclear Medicine最新文献

{"title":"[18F]-FDG PET/CT in the Initial Staging of Squamous Cell Cancer of the Anal Canal: Results of a Prospective Multicenter Registry","authors":"Ur Metser, Jelena Lukovic, Aruz Mesci, Pamela MacCrostie, Rosanna Chan, Victor Mak, Lisa Avery, Amit Singnurkar, Deanna L. Langer, Kara Ly, Andres Kohan","doi":"10.2967/jnumed.124.269289","DOIUrl":"https://doi.org/10.2967/jnumed.124.269289","url":null,"abstract":"<p>In patients with squamous cell carcinoma of the anal canal (ACC), disease stage influences treatment plans and determines prognosis. Our purpose was to determine the impact of PET on the initial staging of patients with presumed stages II–IV ACC and to assess the association of disease stage per conventional workup (CW) and PET imaging to patient outcomes. <strong>Methods:</strong> In this multicenter registry, patients with CW stages II–IV ACC or equivocal findings for a specific stage were included. Demographic data and stage according to the American Joint Committee on Cancer (AJCC) version 7 as determined by CW and PET were recorded and compared with overall survival (OS). For patients from 1 of the participating institutions, CW and PET stage according to AJCC versions 7–9 were compared with progression-free survival (PFS) and OS. <strong>Results:</strong> There were 813 patients included. PET upstaged 150 of 531 patients (28.2%) and downstaged 84 of 531 patients (15.8%) and assigned a specific stage to 200 of 232 patients (86.2%) with equivocal findings on CW. Stage IV on PET was predictive of significantly poorer OS (<em>P</em> = 0.005). For the 136 patients with staging according to AJCC versions 7–9, CW stages I–IV per versions 7–9 were not predictive of OS (<em>P</em> = 0.684, 0.329, and 0.083, respectively) or PFS (<em>P</em> = 0.622, 0.606, and 0.115, respectively). However, PET stages I–IV per versions 7–9 were associated with OS (<em>P</em> = 0.037, 0.003, 0.003, respectively) and PFS (<em>P</em> = 0.004, &lt;0.001, &lt;0.001, respectively), with version 9 best discriminating PFS for stages II and III. <strong>Conclusion:</strong> In patients with presumed stages II–IV ACC, PET stage differs in up to 44% from CW. PET assigns a specific stage in most patients with equivocal staging on CW. The PET-derived stage was predictive of PFS and OS. Because of its superior prognostication, PET should be used routinely to stage patients with ACC clinical stage II or above.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143570367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imaging Synaptic Density in Aging and Alzheimer Disease with [18F]SynVesT-1","authors":"Joseph Giorgio, David N. Soleimani-Meigooni, Mustafa Janabi, Suzanne L. Baker, Xi Chen, Tyler N. Toueg, Robby Weimer, Bastian Zinnhardt, Ari Green, Gil D. Rabinovici, William J. Jagust","doi":"10.2967/jnumed.124.269005","DOIUrl":"https://doi.org/10.2967/jnumed.124.269005","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.124.269005absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"87 1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143570369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biodistribution, Safety Profile, and Radiation Dosimetry of [18F]SYN2, a PET Cardiac Perfusion Tracer, in Healthy Subjects","authors":"Juhani Knuuti, Małgorzata Kobylecka, Seweryn Krajewski, Lukasz Steczek, Karina Gotowicz, Joanna Towpik, Kari Kalliokoski, Tuula Tolvanen, Magdalena Kostkiewicz, Przemysław Kozanecki, Joanna Włostowska, Mirosław Dziuk, Leszek Królicki, Jacek Bil, Piotr J. Slomka, Timothy M. Bateman, Mouaz H. Al-Mallah, Panithaya Chareonthaitawee, Prem Soman, Cezary Kozanecki","doi":"10.2967/jnumed.124.268872","DOIUrl":"https://doi.org/10.2967/jnumed.124.268872","url":null,"abstract":"<p>A first-in-human phase I clinical study aimed to assess the safety profile, radiation dosimetry, and biodistribution of a potential cardiac PET myocardial perfusion imaging tracer, [¹⁸F]SYN2 (¹⁸F-labeled acridine derivative), in healthy subjects. <strong>Methods:</strong> [¹⁸F]SYN2 intravenous administration with PET imaging was performed on healthy volunteers, and sequential whole-body imaging was performed over 4 h. Blood and urine samples were collected for up to 240 min. Safety follow-up visits took place at 2, 5, and 14 d after the administration. <strong>Results:</strong> Ten subjects (8 women and 2 men) completed all study procedures. The mean age was 38.1 ± 8.8 y, and the mean body mass index was 22.7 ± 3.0 kg/m². The mean administered dose of radioactivity was 258 MBq (range, 246–272 MBq). There were no drug-related adverse events, and the tracer was well tolerated in all subjects. The mean whole-body effective radiation dose for [¹⁸F]SYN2 was 0.0195 mSv/MBq. The tracer was rapidly taken up by the myocardial wall and cleared from plasma, leading to good image quality within minutes of tracer injection. <strong>Conclusion:</strong> On the basis of the safety profile, radiation dosimetry, and biodistribution of [¹⁸F]SYN2, it appears to be a promising agent for clinical PET myocardial perfusion imaging and to warrant further clinical studies.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"67 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143570364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in Fibroinflammatory Activity Shown on 68Ga-FAPI-04 and 18F-FDG PET/CT in the Two Subtypes of IgG4-Related Disease","authors":"Silu Liu, Qingqing Pan, Hongzhe Zhang, Linyi Peng, Wen Zhang, YunLu Feng, Dong Wu, Yaping Luo","doi":"10.2967/jnumed.124.268943","DOIUrl":"https://doi.org/10.2967/jnumed.124.268943","url":null,"abstract":"<p>IgG4-related disease (IgG4-RD) is a highly heterogeneous autoimmune disease. Recently, 2 subtypes of IgG4-RD, proliferative and fibrotic, were defined according to patients’ clinicopathologic characteristics. The purpose of this study was to determine the difference in fibroinflammatory activity shown on ⁶⁸Ga-FAPI-04 and ¹⁸F-FDG PET/CT in the proliferative and fibrotic IgG4-RD subtypes. <strong>Methods:</strong> Thirty-seven newly diagnosed IgG4-RD patients (29 of the proliferative subtype and 8 of the fibrotic subtype) who had undergone ⁶⁸Ga-FAPI-04 and ¹⁸F-FDG PET/CT were enrolled. SUV_max and target-to-background ratio (TBR) of IgG4-RD lesions were measured. To evaluate the weight of fibroinflammatory activity, the PET index of a lesion was calculated as the quotient of SUV_max or TBR of ⁶⁸Ga-FAPI-04 and that of ¹⁸F-FDG. For the assessment of the global disease in an individual patient, the PET index was defined as the ratio of SUV_mean of all involved lesions in ⁶⁸Ga-FAPI-04 PET/CT to that in ¹⁸F-FDG. <strong>Results:</strong> The ¹⁸F-FDG uptake values of the most prominent lesions in the proliferative and fibrotic subtypes were similar; however, the proliferative subtype showed significantly higher uptake of ⁶⁸Ga-FAPI-04 than did the fibrotic subtype (SUV_max, 17.67 ± 7.46 vs. 10.93 ± 2.22, <em>P</em> = 0.005; TBR, 15.49 ± 8.23 vs. 9.25 ± 3.00, <em>P</em> = 0.015). The PET index of proliferative-subtype patients was higher than that of fibrotic-subtype patients (1.46 ± 0.41 vs. 1.14 ± 0.39, <em>P</em> = 0.039). The PET index of pancreatobiliary disease was significantly higher than that of head-and-neck disease, fibrosis or aortitis, lymph nodes, and another disease subtype (<em>P</em> &lt; 0.05). After first-line treatment, patients with a PET index of at least 1.5 had significantly shorter relapse-free survival than those with a PET index of less than 1.5 (22.0 mo vs. not reached, <em>P</em> &lt; 0.0001; hazard ratio, 13.46; 95% CI, 2.236–81.03). <strong>Conclusion:</strong> The proliferative subtype of IgG4-RD had a greater weight of fibroinflammatory activity than that of the fibrotic subtype. The PET index, a marker of the weight of fibroinflammatory activity, is predictive of relapse-free survival of IgG4-RD.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"318 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143570366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of [68Ga]Ga-Fibroblast Activation Protein Inhibitor–04 and [18F]FDG PET Imaging for Solitary Fibrous Tumor and Preliminary Application of FAP-Targeted Radiopharmaceutical Therapy","authors":"Rongxi Wang, Jiarou Wang, Jialin Xiang, Huimin Sui, Linlin Li, Chenhao Jia, Xingtong Peng, Xiaoyuan Chen, Zhaohui Zhu, Jingjing Zhang","doi":"10.2967/jnumed.124.268258","DOIUrl":"https://doi.org/10.2967/jnumed.124.268258","url":null,"abstract":"<p>Solitary fibrous tumor (SFT) is a rare sarcoma of mesenchymal origin. Although generally benign, SFTs carry the risk of recurrence and metastasis, with limited effective treatment options. The aims of this study are to compare the performance of fibroblast activation protein inhibitor (FAPI), [⁶⁸Ga]Ga-DOTA-FAPI-04 (denoted as [⁶⁸Ga]Ga-FAPI-04), and conventional [¹⁸F]FDG PET/CT in patients with recurrent or metastatic SFTs head to head and to preliminarily explore the value of FAP-targeted radiopharmaceutical therapy with ¹⁷⁷Lu for SFT patients. <strong>Methods:</strong> Thirty-one participants (21 men, 44 ± 13 y) with suspected recurrent or metastatic SFTs underwent both [¹⁸F]FDG and [⁶⁸Ga]Ga-FAPI-04 PET/CT within 1 wk. The positive-lesion rates of the 2 PET/CT scans in the different organs involved and the uptake values (SUV_max) were compared. Four patients with high [⁶⁸Ga]Ga-FAPI-04 uptake received single-cycle therapy of 2.22 GBq of a [¹⁷⁷Lu]Lu-labeled, FAP-targeted radiopharmaceutical, [¹⁷⁷Lu]Lu-Evans blue–FAPI, and were followed up for 4 mo. <strong>Results:</strong> In 522 local recurrences and distant metastases in the 31 patients, [⁶⁸Ga]Ga-FAPI-04 PET detected significantly more lesions than did [¹⁸F]FDG (87.0% vs. 45.4%, <em>P</em> &lt; 0.001). In terms of lesion uptake values, [⁶⁸Ga]Ga-FAPI-04 PET showed a mean SUV_max higher than that of [¹⁸F]FDG in most recurrence or metastatic organs (bone, lung, central nervous system, pancreas, and pleura, <em>P</em> &lt; 0.001; kidney and abdominopelvic cavity, <em>P</em> = 0.001; muscle and pericardium, <em>P</em> &lt; 0.05). Four patients tolerated [¹⁷⁷Lu]Lu-Evans blue–FAPI well. The total-body absorbed dose and the effective dose were 4.02E−01 ± 3.54E−02 Gy and 4.01E+02 ± 4.18E+01 mSv, respectively. Subsequent follow-up with [⁶⁸Ga]Ga-FAPI-04 PET showed that these patients were in stable condition. <strong>Conclusion:</strong> [⁶⁸Ga]Ga-FAPI-04 may be a promising PET agent for the assessment of SFTs. Given the lack of effective treatments for advanced SFTs, high FAP expression in this type of tumor is expected to become a potential treatment target.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143570381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Total-Body Parametric Imaging Using Relative Patlak Plot","authors":"Siqi Li, Yasser G. Abdelhafez, Lorenzo Nardo, Simon R. Cherry, Ramsey D. Badawi, Guobao Wang","doi":"10.2967/jnumed.124.268496","DOIUrl":"https://doi.org/10.2967/jnumed.124.268496","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.124.268496absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MHC-I–Driven Antitumor Immunity Counterbalances Low Absorbed Doses of Radiopharmaceutical Therapy","authors":"Julie Constanzo, Aliasghar Parach, Timothee David, Joshua Karam, Frank Bruchertseifer, Alfred Morgenstern, Marta Jarlier, Manuel Bardiès, Emmanuel Deshayes, Amelie Gudin-de-Vallerin, Florence Boissière-Michot, Evelyne Lopez-Crapez, Jean-Pierre Pouget","doi":"10.2967/jnumed.124.268857","DOIUrl":"https://doi.org/10.2967/jnumed.124.268857","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.124.268857absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"185 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular Imaging of Pulmonary Fibrosis","authors":"Margaret B. Allison, Ciprian Catana, Iris Y. Zhou, Peter Caravan, Sydney B. Montesi","doi":"10.2967/jnumed.124.267852","DOIUrl":"https://doi.org/10.2967/jnumed.124.267852","url":null,"abstract":"<p>Fibrosing lung diseases affect over 160,000 individuals in the United States alone and can carry a prognosis that is worse than many cancers. Antifibrotic treatments modify only the rate of fibrosis progression, and more effective therapies are urgently needed. Molecular imaging enables visualization of disease pathogenesis in progress. It provides a noninvasive means to monitor and quantify dysregulated molecular fibrotic pathways and shows great promise in aiding the diagnosis and disease activity monitoring of pulmonary fibrosis. Here, we review molecular imaging probes under development for use in pulmonary fibrosis. We provide our opinion on current challenges in translating preclinical molecular imaging probes into clinical successes, as well as future directions for expanding their use in drug development.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"51 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical Therapy","authors":"Fabio Turco, Silke Gillessen, Ken Herrmann, Gaetano Paone, Aurelius Omlin","doi":"10.2967/jnumed.124.267730","DOIUrl":"https://doi.org/10.2967/jnumed.124.267730","url":null,"abstract":"<p>The treatment landscape of prostate cancer is quite complex because of the many therapeutic options available in different disease settings (hormonal treatments, chemotherapy, poly(adenosine diphosphate ribose) polymerase inhibitors, radiopharmaceutical therapy). Since in most cases we do not have comparative studies between these different agents, the best therapeutic sequence in patients with prostate cancer remains unsolved. In this review, we describe the different systemic therapeutic options available in each disease setting from localized disease to metastatic castration-resistant disease. We also indicate when to use each of these therapeutic options in the therapeutic sequence on the basis of the results of the available studies. A special focus of this review is the place of prostate-specific membrane antigen radiopharmaceutical therapy in the treatment algorithms.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"85 3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating Radiation Safety After Radiopharmaceutical Therapies: Proposed Workflow and Essential Guidelines for Nonspecialists","authors":"Anna Mench, Celeste Winters, Erik Mittra, Laszlo Szidonya, Catherine Hess, Dennis Barbon, Nadine Mallak","doi":"10.2967/jnumed.124.268522","DOIUrl":"https://doi.org/10.2967/jnumed.124.268522","url":null,"abstract":"<p>With the increasing use of radiopharmaceutical therapies, there is a critical need to appropriately inform health care professionals (HCPs) who are unfamiliar with these therapies about the radiation safety precautions required when managing recently treated patients. Clear and easily accessible instructions are essential for minimizing radiation exposure to medical staff and simultaneously reducing fear of interacting with a radioactive patient, as these factors can impact the delivery of adequate and timely medical care. In this paper, we present a workflow designed to provide clear guidelines and safety protocols for HCPs who may encounter postradiopharmaceutical therapy patients during urgent medical visits or hospital admissions. This workflow consists of 2 key strategies: an electronic medical record flag system and a physical wristband that alerts the HCP that the patient may be radioactive and includes a link to a website with detailed information. These tools ensure that HCPs who encounter these patients will have immediate access to essential radiation safety information, thereby safeguarding staff and maintaining the continuity of patient care.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}